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Once cutaneous melanoma metastasizes prognosis of patients is generally poor in spite of recent therapeutic advances. Prognostic biomarkers are needed to better identify those patients with primary melanoma who are at increased risk of metastatic disease. Gene expression signatures have been defined that are associated with metastatic capacity of primary melanoma and survival (Winnepenninckx et al., 2006; Conway et al., 2009) . Genomic characterization has revealed diverse recurrent genetic alterations including those that drive the tumorigenic process. However, the underlying molecular changes that confer the capacity to melanoma cells to migrate and colonize distant body sites remain to be defined. Promoter CpG island hypermethylation constitutes a mechanism responsible for deregulated expression of genes involved in metastasis.
We and others have identified epigenetic alterations in melanoma affecting genes with a potential role in tumour cell dissemination including CDH11 and SERPINB5 (Carmona et al., 2012; Dahl et al., 2015; Gao et al., 2013) . Additionally a 17-gene methylation signature was found to predict disease course of stage IIIC melanoma patients (Sigalotti et al., 2012) . As epigenetic biomarker for metastasis, promoter hypermethylation has the advantage that it is stable and can be reliably detected in clinical samples. The purpose of this study was to identify methylation events that can predict development of lethal metastatic disease in patients with primary cutaneous melanoma.
To this end, we collected clinical follow-up data of 24 patients with primary melanoma whose tumours had been previously subjected to genome-wide DNA methylation profiling using Illumina 27K arrays, analyzing methylation of 14,495 genes (Gao et al., 2013) . Thirteen patients had developed distant metastases, all of whom died due to melanoma, and in 11 patients no metastatic dissemination or tumour recurrence had been detected during a follow-up period of at least six years after diagnosis. We compared methylation profiles from primary melanomas of patients who developed lethal distant organ metastasis (M+) to those from primary melanomas of patients who had not developed metastasis (M-). CpG probes with an average -value difference (a measure of differential DNA methylation reflecting fluorescence intensity ratios between methylated and unmethylated alleles) higher than 0.20 between M+ and M-primary melanomas were considered indicative of hypermethylation of the corresponding gene promoter region. This re-analysis yielded six candidate hypermethylated genes in melanoma with metastatic behavior (M+): MCHR1, SYNPO2, C1orf106, HIST1H3G, ZNF35, and GNMT ( Figure 1a ). We did not find genes hypomethylated in melanoma with metastatic behavior. Validation of these six genes in an independent series of 20 fresh-frozen M+ primary melanomas and 25 M-primary melanomas using bisulphite melting curve analysis (BMCA) showed promoter hypermethylation of MCHR1 and SYNPO2 to be associated with metastatic behavior (Supplementary Table S1 ).
We proceeded with promoter methylation analysis of MCHR1 and SYNPO2 in an independent series of 113 formalin-fixed paraffin-embedded (FFPE) primary invasive cutaneous melanoma samples with available melanoma-specific survival data using methylation-specific PCR (Supplementary Table S2a -c and Supplementary Materials and Methods) . This demonstrated for the MCHR1 promoter a gradual, but not absolute methylation difference between metastatic and non-metastatic melanoma samples, limiting its use as prognostic biomarker. There was a marked difference in SYNPO2 promoter methylation between metastatic and non-metastatic melanomas (Figure 1b ). Primary melanomas with SYNPO2 promoter hypermethylation had a significantly shorter survival (hazards ratio for melanoma-related death 2.01, 95% confidence interval 1.06-3.82; P<0.034 in univariate analysis) (Figure 2a) . Importantly, SYNPO2 promoter hypermethylation remained a statistically significant prognostic factor after adjusting for tumour thickness (hazards ratio for melanoma-related death 2.02, 95% confidence interval 1.05-3.89, P<0.034 in multivariate analysis) (Supplementary Table S3 ). When considering tumour thickness, age (as continuous variables), gender and ulceration as covariates in multivariate analysis, still an association of SYNPO2 methylation and reduced melanoma-specific survival was observed that did not reach statistical significance in this sample series. Table S2d ) (Conway et al., 2009; Jewell et al., 2015) . Illumina DASL HT12 v4 arrays were used to measure whole genome gene expression in FFPE tumours and after quantile normalisation melanomaspecific survival analysis was conducted (Supplementary Materials and Methods). Two SYNPO2 probes were available on the DASL array (ILMN_1688220 and ILMN_1730218). The association of low expression with shorter melanoma-specific survival was statistically significant for ILMN_1688220 before and after adjusting for age, gender and tumour thickness in Cox proportional hazards regression (hazards ratio for melanoma-related death 2.04, 95% confidence interval 1.08-3.85, P<0.04) (Figure 2c, Supplementary Table S4 ). The ILMN_1730218 probe showed a similar trend in association with melanoma-specific survival although it did not reach statistical significance after adjusting for these covariates (Supplementary Table S4 ). The gene expression data are therefore consistent with an association between SYNPO2 silencing by promoter methylation and shorter survival. SYNPO2 has multiple isoforms, which may explain a weaker association found for one of the probes (De Ganck et al., 2008) . Summarizing, SYNPO2 hypermethylation and diminished expression are associated with shorter melanoma-specific survival. Prognostic significance of SYNPO2 hypermethylation and gene expression is independent of tumour thickness.
In line with our observations in melanoma, SYNPO2 methylation was found to associate with tumor aggressiveness and poor clinical outcome in patients with bladder and colon cancer (Alvarez-Mugica et al., 2010; Esteban et al., 2012) . In aggressive prostate cancer the locus on chromosome 4q26 harboring SYNPO2 is frequently deleted (Lin et al., 2001 ). SYNPO2 encodes myopodin, a member of synaptopodin family of actin-binding proteins that regulate cell shape and motility. In prostate cancer cells myopodin inhibits tumor growth and invasion in vitro and in vivo (Jing et al., 2004) . The ability of myopodin to inhibit tumor cell migration depends on its binding to zyxin and integrin-link kinase (Yu and Luo, 2006; Yu and Luo, 2011) . It is thought that myopodin primarily affects cell migration and invasion by inducing changes in actin cytoskeleton networks (Kai and Duncan, 2013) . The potential involvement of myopodin in melanoma cell dissemination deserves further examination. The clinical value of SYNPO2 methylation in predicting metastatic behaviour of primary melanoma should be addressed in larger prospective studies, possibly combined with other candidate epigenetic markers.
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